Market Overview

UPDATE: J.P. Morgan Lowering Price Target on HealthSouth


J.P. Morgan Chase & Co. is out with a research report on HealthSouth Corp (NYSE: HLS) and it is lowering its price target to $25 from $28, but is keeping its Neutral rating on shares.

In a note to clients, J.P. Morgan Chase & Co. writes, "HealthSouth reported 3Q11 EPS of $0.17/share compared to our estimate of $0.21 through adjusted EBITDA came in $7.5mm (7.3%) above our outlook at $110.5mm. Against our outlook the better performance was due to lower other operating expense, supplies and bad debt. HLS raised its EBITDA outlook to $450-$455mm, from the prior range of $447-$453mm. Additionally, the company announced a $125mm buyback, representing about 6% of the diluted share count. We are adjusting estimates and maintaining our Neutral rating with an updated Dec-2012 price target of $25."

Shares of HLS closed at $18.43 yesterday.

Posted-In: J.P. Morgan Chase & Co.Analyst Color Price Target Analyst Ratings


Related Articles (HLS)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Financial Breakfast: Morning News Summary for October 28, 2011

Sterne Agee Lowers EPS Estimates on Legg Mason